Faculty Directory

Ameet Sarpatwari

Institute Faculty

Ameet Sarpatwari, PhD, JD, is a faculty member within the Division of Health Policy and Insurance Research (HPI) in the Department of Population Medicine at the Harvard Pilgrim Health Care Institute and Harvard Medical School. His research draws upon his interdisciplinary training as an epidemiologist and lawyer and focuses on the effects of laws and regulations on therapeutic development, approval, use, and related public health outcomes.  

Dr. Sarpatwari's work has been highly influential. His writing and resulted in multiple invitations to testify before Congress and state legislatures, to discuss proposed legislation with Hill staffers, and to be approached routinely for insight on pharmaceutical policy by reporters from such prominent news sources as the New York Times, Washington Post, and NPR.

In addition to his primary position with HPI, Dr. Sarpatwari is also a faculty member in the Center for Bioethics at Harvard Medical School, the Department of Health Policy and Management at the Harvard T.H. Chan School of Public Health (“Harvard Chan School”), and the Harvard-MIT Center for Regulatory Science. At the Harvard Chan School, he serves as the Faculty Director of the JD/MPH program and teaches a highly acclaimed class on public health law.

Dr. Sarpatwari completed his undergraduate studies at the University of Virginia, where he was a Jefferson Scholar. He studied epidemiology at the University of Cambridge, where he received a Ph.D. He subsequently studied law at the University of Maryland as a John L. Thomas Leadership Scholar. Following his legal studies, he joined the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital and Harvard Medical School as a post-doctoral fellow. He remained with PORTAL, serving as its Assistant Director for several years.  

Areas of Expertise

  • Pharmaceutical policy
  • Prescription drug pricing and access
  • Patents and regulatory exclusivities
  • Public health law